← Leaderboards
Shu-Hsia Chen
Methodist Hospital Research Institute
$16,255,143
Attributed
$17,476,177
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,476,177 · 10
By mechanism
R01$16,938,757 · 8
R21$418,770 · 1
R29$118,650 · 1
Top collaborators
- Xuewu Liu2 shared
- Junhua Mai2 shared
- Ping-Ying Pan2 shared
Most similar at Methodist Hospital Research Institute
Same institution · by research overlap
- Haifa Shen$7,162,956
- Xuewu Liu$2,224,398
- Junhua Mai$789,361
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMediatingCytokineT-LymphocyteResponseMalignant NeoplasmsMyelogenousPhenotypeSignal TransductionImmunePreventBaseTumor ImmunityIn VivoCellsReceptorTumor BurdenSignal PathwayIn VitroRegulationLigandsLeadNeoplasm MetastasisImmunotherapy
Grant awards (52)
Novel gene delivery to modulate the tumor microenvironment and antigen-specific antitumor immunity$610,783
R01 · FY2025 · CA · contact PI
Novel gene delivery to modulate the tumor microenvironment and antigen-specific antitumor immunity$610,783
R01 · FY2024 · CA · contact PI
Mechanism of Intratumoral Transport of Particulate Drugs$456,480
R01 · FY2023 · CA · contact PI
Mechanism of Intratumoral Transport of Particulate Drugs$458,897
R01 · FY2022 · CA · contact PI
LILRB modulates tumor microenvironment and promotes tumor progression$414,496
R01 · FY2022 · CA · contact PI
Modulation of tumor inflammatory factor for immune therapy$463,463
R01 · FY2021 · CA · contact PI
LILRB modulates tumor microenvironment and promotes tumor progression$436,037
R01 · FY2021 · CA · contact PI
Modulation of tumor inflammatory factor for immune therapy$463,463
R01 · FY2020 · CA · contact PI
LILRB modulates tumor microenvironment and promotes tumor progression$436,037
R01 · FY2020 · CA · contact PI
Modulation of tumor inflammatory factor for immune therapy$449,561
R01 · FY2019 · CA · contact PI
LILRB modulates tumor microenvironment and promotes tumor progression$1
R01 · FY2019 · CA · contact PI
Modulation of tumor inflammatory factor for immune therapy$463,463
R01 · FY2018 · CA · contact PI
LILRB modulates tumor microenvironment and promotes tumor progression$435,587
R01 · FY2018 · CA · contact PI
Intervention of Immune Tolerance by Small Molecules$311,223
R01 · FY2018 · CA · contact PI
Modulation of tumor inflammatory factor for immune therapy$461,550
R01 · FY2017 · CA · contact PI
LILRB modulates tumor microenvironment and promotes tumor progression$457,636
R01 · FY2017 · CA · contact PI
Intervention of Immune Tolerance by Small Molecules$251,652
R01 · FY2017 · CA · contact PI
Intervention of Immune Tolerance by Small Molecules$89,509
R01 · FY2017 · CA · contact PI
Intervention of Immune Tolerance by Small Molecules$341,161
R01 · FY2016 · CA · contact PI
Myeloid Suppressor Cell-Mediated Immune Suppression of Tumor Specific T Cells$348,662
R01 · FY2015 · CA · contact PI
Intervention of Immune Tolerance by Small Molecules$341,161
R01 · FY2015 · CA · contact PI
Intervention of Immune Tolerance by Small Molecules$341,161
R01 · FY2014 · CA · contact PI
Myeloid Suppressor Cell-Mediated Immune Suppression of Tumor Specific T Cells$338,202
R01 · FY2014 · CA · contact PI
Myeloid Suppressor Cell-Mediated Immune Suppression of Tumor Specific T Cells$327,742
R01 · FY2013 · CA · contact PI
Myeloid Suppressor Cell-Mediated Immune Suppression of Tumor Specific T Cells$348,662
R01 · FY2012 · CA · contact PI
Intervention of immune tolerance by small molecules to enhance immune therapy$339,483
R01 · FY2012 · CA · contact PI
Myeloid Suppressor Cell-Mediated Immune Suppression of Tumor Specific T Cells$348,662
R01 · FY2011 · CA · contact PI
Intervention of immune tolerance by small molecules to enhance immune therapy$339,483
R01 · FY2011 · CA · contact PI
Myeloid Suppressor Cell-Mediated Immune Suppression of Tumor Specific T Cells$169,500
R01 · FY2011 · CA · contact PI
Intervention of immune tolerance by small molecules to enhance immune therapy$349,982
R01 · FY2010 · CA · contact PI
Combination gene therapy for metastatic colon cancer$287,106
R01 · FY2010 · CA · contact PI
Myeloid suppressor cell-mediated immune suppression of tumor specific T cells$262,923
R01 · FY2010 · CA · contact PI
Intervention of immune tolerance by small molecules to enhance immune therapy$349,982
R01 · FY2009 · CA · contact PI
Combination gene therapy for metastatic colon cancer$287,106
R01 · FY2009 · CA · contact PI
Myeloid suppressor cell-mediated immune suppression of tumor specific T cells$262,923
R01 · FY2009 · CA · contact PI
Intervention of immune tolerance by small molecules to enhance immune therapy$349,982
R01 · FY2008 · CA · contact PI
Combination gene therapy for metastatic colon cancer$287,106
R01 · FY2008 · CA · contact PI
Myeloid suppressor cell-mediated immune suppression of tumor specific T cells$262,923
R01 · FY2008 · CA · contact PI
Combination gene therapy for metastatic colon cancer$287,106
R01 · FY2007 · CA · contact PI
Myeloid suppressor cell-mediated immune suppression of tumor specific T cells$262,923
R01 · FY2007 · CA · contact PI
Combination gene therapy for metastatic colon cancer$295,681
R01 · FY2006 · CA · contact PI
Myeloid suppressor cell-mediated immune suppression of tumor specific T cells$270,776
R01 · FY2006 · CA · contact PI
Myeloid suppressor cell-mediated immune suppression$206,895
R21 · FY2006 · DK · contact PI
Combination gene therapy for metastatic colon cancer$301,710
R01 · FY2005 · CA
Myeloid suppressor cell-mediated immune suppression$211,875
R21 · FY2005 · DK
Combination gene therapy for metastatic colon cancer$301,710
R01 · FY2004 · CA
Combination gene therapy for metastatic colon cancer$301,710
R01 · FY2003 · CA
IMMUNE ACTIVATION OF NK AND TUMOR SPECIFIC T CELLS BY IN$363,496
R01 · FY2002 · CA
Combination gene therapy for metastatic colon cancer$301,710
R01 · FY2002 · CA
IMMUNE ACTIVATION OF NK AND TUMOR SPECIFIC T CELLS BY IN$353,536
R01 · FY2001 · CA
IMMUNE ACTIVATION OF NK AND TUMOR SPECIFIC T CELLS BY IN$343,866
R01 · FY2000 · CA
COMBINATION GENE THERAPY FOR METASTATIC COLON CARCINOMA$118,650
R29 · FY2000 · CA